85 withdrawn. 85 Phase 2, 18 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 85 | Withdrawn 85 |
| Phase 1 | 18 | Withdrawn 18 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma Belantamab mafodotin - Relapsed/Refractory Multiple Myeloma | Phase 2 | Withdrawn | Cristiana Costa Chase, DO | 2026-11-01 | 2026-09-28 | |
| Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Daratumumab, Lenalidomide, Bortezomib - Newly Diagnosed Multiple Myeloma, Multiple Myeloma | Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2026-07-01 | 2026-06-09 | |
| A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Withdrawn | Regeneron Pharmaceuticals | 2026-06-05 | 2026-06-18 | |
| Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells Commercial CAR-T, Investigational CAR-T - Malignancy, Cancer | Phase 1 / Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2025-01-20 | 2026-01-06 | |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM Siltuximab, Teclistamab(FDA-approved) - Multiple Myeloma, Cytokine Release Syndrome | Phase 2 | Withdrawn | Jack Khouri, MD | 2025-01-01 | 2025-03-03 | |
| Marizomib Central Nervous System (CNS) Marizomib, Pomalidomide, Dexamethasone - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2024-03-01 | 2024-07-16 | |
| Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant Selinexor, Lenalidomide, Dexamethasone - Multiple Myeloma, Myeloma-Associated Amyloidosis | Phase 2 | Withdrawn | Washington University School of Medicine | 2024-01-05 | 2024-07-10 | |
| Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Mezigdomide, Ixazomib, Dexamethasone - Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Kathleen Dorritie | 2023-10-02 | 2024-11-19 | |
| Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma SLAMF7 FPBMC - Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | University of Virginia | 2023-08-01 | 2023-11-21 | |
| BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT anti-BCMA CAR-T - Multiple Myeloma | Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2023-05-29 | 2026-04-29 | |
| Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients. [68Ga]Ga-PentixaFor - Multiple Myeloma | Phase 2 | Withdrawn | Nantes University Hospital | 2023-03-14 | 2023-11-15 | |
| Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases LM-305, Dexamethasone - Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases | Phase 1 / Phase 2 | Withdrawn | LaNova Medicines Limited | 2023-01-18 | 2023-11-18 | |
| Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. Pembrolizumab, Belantamab mafodotin, Dexamethasone - Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Withdrawn | Hackensack Meridian Health | 2022-12-01 | 2023-01-27 | |
| Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM Daratumumab, Pomalidomide - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Alliance Foundation Trials, LLC. | 2022-10-01 | 2023-01-27 | |
| Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma Elotuzumab, Selinexor, and Dexamethasone (ESd) - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Withdrawn | Tulane University School of Medicine | 2022-04-27 | 2022-05-04 | |
| Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy Pembrolizumab - Plasma Cell Myeloma | Phase 2 | Withdrawn | Emory University | 2022-04-11 | 2024-07-03 | |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) Biopsy, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-02-22 | 2024-05-06 | |
| Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy Lenalidomide Pill, Dexamethasone, Daratumumab - Multiple Myeloma | Phase 2 | Withdrawn | Attaya Suvannasankha | 2021-12-06 | 2022-12-08 | |
| Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma Daratumumab - Multiple Myeloma | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-07-02 | 2022-04-21 | |
| Study of Dara-Pembro for Multiple Myeloma Patients Pembrolizumab - Multiple Myeloma | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-06-09 | 2022-04-26 |
Showing 20 of 85. Sign in to see all of them.
Recurrence (13) · Neoplasms, Plasma Cell (12) · Lymphoma (7) · Leukemia (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Burkitt Lymphoma (5) · Hematologic Neoplasms (5) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (5) · Lymphoma, Non-Hodgkin (5) · Neoplasms (5) · Congenital Abnormalities (4) · Leukemia, Myeloid, Accelerated Phase (4)
Blood Protein Disorders (85) · Hemic and Lymphatic Diseases (85) · Hemorrhagic Disorders (85) · Hemostatic Disorders (85) · Immunoproliferative Disorders (85) · Neoplasms by Histologic Type (85) · Paraproteinemias (85) · Vascular Diseases (85) · Cardiovascular Diseases (84) · Hematologic Diseases (84) · Immune System Diseases (84) · Lymphoproliferative Disorders (84) · Neoplasms (80) · Neoplasms, Plasma Cell (73) · Pathologic Processes (22)
Dexamethasone (37) · Bortezomib (17) · Lenalidomide (15) · Calcium Dobesilate (14) · Melphalan (11) · daratumumab (9) · Cyclophosphamide (7) · elotuzumab (7) · pembrolizumab (6) · pomalidomide (6) · carfilzomib (5) · dexamethasone acetate (5) · ixazomib (5) · Thalidomide (4) · dexamethasone 21-phosphate (4)
National Cancer Institute (NCI) (9) · University of Arkansas (7) · M.D. Anderson Cancer Center (4) · UNC Lineberger Comprehensive Cancer Center (3) · Assistance Publique - Hôpitaux de Paris (2) · Dana-Farber Cancer Institute (2) · Karyopharm Therapeutics Inc (2) · Mayo Clinic (2) · Sun Yat-sen University (2) · University of California, San Francisco (2) · Wake Forest University Health Sciences (2) · Washington University School of Medicine (2) · AbbVie (1) · Academic and Community Cancer Research United (1) · Alliance Foundation Trials, LLC. (1)
United States (44) · Canada (4) · France (4) · Australia (3) · China (3) · Israel (3) · Spain (3) · Italy (2) · Belgium (1) · Brazil (1) · Germany (1) · Greece (1) · South Korea (1) · Sweden (1) · Taiwan (1)
Carl O Landgren, M.D. (3) · Faith Davies, MD (2) · Ajay K Nooka, MD,MPH,FACP (1) · Antonio Palumbo, MD (1) · Ashley Rosko, MD (1) · Attaya Suvannasankha, MD (1) · Christoph Heuck, MD (1) · Claudio Brunstein, MD, PhD (1) · Clifton Mo, MD (1) · Cristiana Costa Chase, DO (1) · Depei Wu (1)
PMID 23927993, PMID 28148715, PMID 31433920
U10CA180820 (3), 2017 (2), P30CA015083 (2), P30CA072720 (2), 2015 (1), 2025 (1), P01CA065493 (1), P30CA016058 (1), P30CA043703 (1), P30CA138292 (1), U01CA132194 (1), U10CA032102 (1), U24CA196172 (1), UM1CA186644 (1)